TY  - CHAP
M1  - Book, Section
TI  - Genomic and Precision Medicine in Anesthesia Practice
A1  - Podgoreanu, Mihai V.
A1  - Kertai, Miklos D.
A2  - Longnecker, David E.
A2  - Mackey, Sean C.
A2  - Newman, Mark F.
A2  - Sandberg, Warren S.
A2  - Zapol, Warren M.
PY  - 2017
T2  - Anesthesiology, 3e
AB  - KEY  POINTSEarly  candidate  gene  studies  and  more  recent  genomewide  association  studies  suggest  that  susceptibility  to  adverse  perioperative  events  including  cardiac  (myocardial  infarction,  ventricular  dysfunction,  atrial  fibrillation),  neurologic,  and  renal,  among  other  events,  is  genetically  determined.  A  particular  focus  is  now  placed  on  determining  whether  a  specific  genetic  variant  warrants  clinical  action.Potential  applications  of  biomarkers  in  perioperative  medicine  and  critical  care  include  prognosis,  diagnosis,  and  monitoring  of  adverse  outcomes,  as  well  as  informing  and  refining  therapeutic  decisions.  Very  few  so  far  have  been  rigorously  evaluated  to  demonstrate  additive  performance  to  existing  risk  stratification  models  (clinical  validity)  or  change  therapy  (clinical  utility).  Most  promising  among  those  are  natriuretic  peptides  and  C-reactive  protein  for  cardiovascular  risk  prediction,  postoperative  troponin  surveillance  to  diagnose  myocardial  injury,  and  procalcitonin  to  assess  infection  in  the  critically  ill.Ongoing  systematic  evaluation  of  existing  genomic  evidence  to  make  clinical  decisions  in  the  perioperative  continuum,  update  practice  guidelines,  and  reimburse  the  generation  and  use  of  genomic  information  is  required  to  facilitate  its  translation  to  medical  practice.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessanesthesiology.mhmedical.com/content.aspx?aid=1144136761
ER  -